Process of making flowable hemostatic compositions and devices containing such compositions
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-038/00
A61K-031/14
출원번호
UP-0348860
(2006-02-07)
등록번호
US-7833965
(2011-01-16)
발명자
/ 주소
Pendharkar, Sanyog M.
Gorman, Anne J.
Zhang, Guanghui
Rivera, Ada
Looney, Dwayne Lee
Craven, Thomas Lee
출원인 / 주소
Ethicon, Inc.
대리인 / 주소
Roberts Mlotkowski Safran & Cole, P.C.
인용정보
피인용 횟수 :
9인용 특허 :
15
초록▼
The present invention includes both sterilized and unsterilized hemostatic compositions that contain a continuous, biocompatible liquid phase having a solid phase of particles of a biocompatible polymer suitable for use in hemostasis and which is substantially insoluble in the liquid phase, and a di
The present invention includes both sterilized and unsterilized hemostatic compositions that contain a continuous, biocompatible liquid phase having a solid phase of particles of a biocompatible polymer suitable for use in hemostasis and which is substantially insoluble in the liquid phase, and a discontinuous, biocompatible gaseous phase, each of which is substantially homogenously dispersed throughout the continuous liquid phase, methods for making such compositions, medical devices that contain sterilized hemostatic compositions disposed therein and methods of making such devices.
대표청구항▼
We claim: 1. A flowable hemostatic composition, comprising: a continuous, biocompatible liquid phase, a solid phase comprising particles of a biocompatible polymer suitable for use in hemostasis and which is substantially insoluble in said liquid phase; and a discontinuous gaseous phase comprising
We claim: 1. A flowable hemostatic composition, comprising: a continuous, biocompatible liquid phase, a solid phase comprising particles of a biocompatible polymer suitable for use in hemostasis and which is substantially insoluble in said liquid phase; and a discontinuous gaseous phase comprising a biocompatible gas, said continuous liquid phase comprising said solid phase and said discontinuous gaseous phase substantially homogenously dispersed there through, wherein the ratio of said liquid phase, said solid phase and said gaseous phase is effective to provide said composition with hemostatic and flowable properties; from four percent by weight to about 20 percent by weight of glycerol, based on the weight of said liquid phase, wherein the average diameter of said particles of said biocompatible polymer is from about 40 to about 1200 microns. 2. The composition of claim 1 wherein said liquid phase is aqueous. 3. The composition of claim 2 wherein said liquid phase comprises saline. 4. The composition of claim 3 wherein said biocompatible polymer is selected from the group consisting of proteins and polysaccharides. 5. The composition of claim 4 wherein said protein is selected from the group consisting of gelatin, collagen, fibrinogen and fibronectin. 6. The composition of claim 5 wherein said protein comprises gelatin. 7. The composition of claim 1 wherein said particles, said liquid phase and said gaseous phase are present in said hemostatic composition at a ratio of from about 1:2:1 to about 1:12:13, based on g:ml:ml. 8. The composition of claim 7 wherein said particles, said liquid phase and said gaseous phase are present in said hemostatic composition at a ratio of from about 1:4:1 to about 1:8:9, based on g:ml:ml. 9. The composition of claim 7 wherein the density of said composition is from about 0.3 g/ml to about 0.9 g/ml. 10. The composition of claim 8 wherein the density of said composition is from about 0.6 g/ml to about 0.8 g/ml. 11. The composition of claim 1 wherein said biocompatible gas is selected from the group consisting of air, nitrogen, carbon dioxide, xenon and argon. 12. The composition of claim 1 further comprising a functionally effective amount of an additive selected from the group consisting of antimicrobial agents, foaming agents, foam stabilizers, surfactants, antioxidants, humectants, thickeners, diluents, lubricants, wetting agents, irradiation stabilizers, plasticizers, heparin neutralizers, procoagulants and hemostatic agents. 13. The composition of claim 12 comprising up to about 1 percent by weight of a quaternary amine, based on the weight of said liquid phase. 14. The composition of claim 13 comprising from about 0.001% to about 0.01% by weight of benzalkonium chloride, based on the weight of said liquid phase. 15. The composition of claim 1 wherein said hemostatic composition is sterile. 16. The composition of claim 12 wherein said hemostatic composition is sterile. 17. The composition of claim 16 wherein said additive is selected from the group consisting of fibrinogen and thrombin.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (15)
Epstein Gordon H. ; Lempert Todd E. ; Martin Brian B., Biological sealant mixture and system for use in percutaneous occlusion of puncture sites and tracts in the human body and method.
Kraus Michael (Frankfurt DEX) Mller Wolfgang (Oberursel DEX), Method of producing thrombin from factor II using calcium ions for the conversion on an anion exchanger.
Miller, Mark E.; Cortese, Stephanie M.; Schwartz, Herbert E.; Oppelt, William G., Polyacid/polyalkylene oxide foams and gels and methods for their delivery.
Senderoff, Richard I.; Meyer, Jeffrey D.; Rollins, Emily N.; Hughes, Steven D.; Garcia, Richard M.; Bishop, Paul D.; Lasser, Gerald W., Hemostatic microspheres.
Gabel, Jonathan B.; Looney, Dwayne L.; Guglielmo, Michael E., Process of making flowable hemostatic compositions and devices containing such compositions.
Pendharkar, Sanyog M.; Gorman, Anne J.; Zhang, Guanghui; Rivera, Ada; Looney, Dwayne Lee; Craven, Thomas Lee, Process of making flowable hemostatic compositions and devices containing such compositions.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.